Founded in 1993 by Trevor Castor, Aphios Corporation’s primary goal was to pursue virus inactivation. In order to achieve this objective, the company developed a technology to disrupt viral particles through the application of SuperFluids™.
WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation today announced that it is the proud recipient of the 2009 Frost & Sullivan North American Excellence in Healthcare Technology Innovation of the Year Award in the field of Enhanced Nanodrug Therapeutic Systems for developing the SuperFluids™ nanodrug solubility, encapsulation and delivery platforms. These platforms are unique in that they create dense phase super solvents with superior thermodynamic properties, allowing them to formulate and deliver drugs to targets that are not resolvable through conventional means.
Founded in 1993 by Trevor Castor, Aphios Corporation’s primary goal was to pursue virus inactivation. In order to achieve this objective, the company developed a technology to disrupt viral particles through the application of SuperFluids™. Under Dr. Castor’s leadership, the company serendipitously realized that by reverse engineering the technology to disrupt viral particles they could now create nanoparticles that can be suitably employed for drug solubilization and delivery. Over the years, the strategic direction of the company has evolved from being a company focused on viral therapeutics to an organization that focuses on related technology diversification across drug solubility and delivery, thereby expanding the scope for innovative therapeutic administration.
There are two fundamental challenges in the fields of vaccine and therapeutic development and administration. Oral delivery of protein macromolecules is the Holy Grail in biotechnology medicine since proteins and peptides are digested by enzymes and acids before reaching the circulation system. Similar degradation occurs with subunit protein, DNA or inactivated vaccine antigens that are degraded before eliciting a proper immune response. Effective nanoencapsulation affords the luxury of both protecting and releasing the biologic therapeutic or vaccine antigen in a controlled manner to maximize their therapeutic efficacy. Similar challenges reside with hydrophobic cancer therapeutics administered intravenously - nanoencapsulation both reduces toxicity and increases efficacy, contributing to improvements in therapeutic index and quality-of-life.
About the Award: Frost & Sullivan’s Technology Innovation Award is bestowed upon a company (or individual) that has carried out new research, which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. This award recognizes the quality and depth of a company’s research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.
About Research Methodology: To choose the award recipient, Frost & Sullivan’s analyst team tracks innovation in key hi-tech markets. The selection process includes primary participant interviews and extensive primary and secondary research via the bottom-up approach. The analyst team shortlists candidates based on a set of qualitative and quantitative measurements. The analysts also consider the pace of research and technology innovation, and the significance or potential relevance of the innovation to the overall industry. The ultimate award recipient is chosen after a thorough evaluation of this research.
About Best Practices: Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Frost & Sullivan: Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan’s Growth Partnerships, visit http://www.frost.com. www.awards.frost.com
